Satellos Bioscience
Developing SAT-3247, an oral muscle-repair therapy for Duchenne muscular dystrophy.
Something off on this page? Send us feedback.
Profile
Develops the investigational oral AAK1 inhibitor SAT-3247 for Duchenne muscular dystrophy and uses the MyoReGenX ex-vivo platform to assess potential therapies for degenerative muscle diseases. Potential monetization includes biopharmaceutical partnerships, self-directed commercialization, or M&A; the single-candidate program has no product revenue.
Develops SAT-3247, an investigational oral small-molecule AAK1 inhibitor designed to restore muscle-stem-cell repair signaling in Duchenne muscular dystrophy without replacing dystrophin. Uses the MyoReGenX ex-vivo screening platform to model the muscle-stem-cell environment and assess targets and compounds for DMD and other degenerative muscle diseases.
Operates across Canada, the United States, and Australia, with clinical studies extending through North America, Europe, the United Kingdom, and other regions.
Runs one operating segment focused on researching small-molecule drug candidates and keeps a small internal team for preclinical development, chemistry, manufacturing, and controls, and clinical development while supervising specialized CROs. Has earned no revenue; potential monetization includes biopharmaceutical partnerships, self-directed commercialization, or M&A. Clinical progress depends on trial and regulatory outcomes, external funding, a single contract manufacturer, and an exclusive, royalty-bearing license with the Ottawa Hospital Research Institute.
Company facts
Key statistics
Year to date +25.5% · Average volume (30d) 37.3K
Analysts
No analyst consensus on record.
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 13, 2026Q2 FY26 | −$0.51 | −$0.56 | −9.7% | — | — | — | −2.00% |
| May 14, 2026Q1 FY26 | −$0.51 | −$0.53 | −3.9% | — | — | — | −2.23% |
| Mar 27, 2026Q4 FY25 | −$0.36 | −$0.47 | −30.6% | — | — | — | −4.52% |
| Nov 14, 2025Q3 FY25 | −$0.33 | −$0.36 | −11.1% | — | — | — | — |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | |
| Gross profit | −$996 | −$1.0K | −$2.0K | −$1.0K | $0 | −$974 | |
| Operating income | −$6.5M | −$6.4M | −$6.0M | −$7.6M | −$10.0M | −$11.9M | |
| Net income | −$6.1M | −$5.6M | −$5.8M | −$7.3M | −$9.8M | −$11.4M | |
| Diluted EPS | −$0.48 | −$0.36 | −$0.36 | −$0.48 | −$0.53 | −$0.55 | |
| Gross margin | — | — | — | — | — | — | |
| Operating margin | — | — | — | — | — | — |
Fiscal years (4-quarter sums)FY18 $0 · FY19 $0 · FY20 $0 · FY24 $0 · FY25 $0
Balance sheet, Jun 30, 2026Cash & short-term investments $61.8M · Total debt $0 · Total assets $65.7M · Shareholders' equity $59.8M
Dividends
No dividends on record.
Ownership
Shares outstanding 1.29M · Float 1.06M · 82.6% free float
A split settled inside the quarter being compared, so quarter-on-quarter change is not shown.
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Franklin Resources Inc | 938.7K | 72.86% | 13F | May 13, 2026 |
| Siren, L.L.C. | 892.1K | 69.25% | 13F | May 14, 2026 |
| Vivo Capital, LLC | 813.7K | 63.16% | 13F | May 20, 2026 |
| Point72 Asset Management, L.P. | 690.8K | 53.62% | 13F | May 15, 2026 |
| Woodline Partners LP | 500.4K | 38.85% | 13F | May 15, 2026 |
Insider tradesForm 4
Nothing filed in the last 12 months.
View detailsPeers
- Sarepta Therapeutics
Broad DMD threat across gene therapy and exon-skipping.
- PTC Therapeutics
Established all-variant corticosteroid therapy in DMD care.
- REGENXBIO
Late-stage microdystrophin gene therapy for broad DMD use.
- Dyne Therapeutics
Near-registration exon-51 therapy for DMD muscle function.
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Satellos Bioscience | $8.83 | −0.62% | $11.2M | — | — | — | — |
| Sarepta Therapeutics | $21.05 | +0.98% | $2.20B | — | 26.3 | 1.1 | −34.3% |
| PTC Therapeutics | $70.59 | +0.73% | $5.85B | — | 58.0 | 5.8 | +101.6% |
| REGENXBIO | $9.65 | −0.21% | $499.4M | — | — | 2.9 | +405.7% |
| Dyne Therapeutics | $25.07 | −0.04% | $4.68B | — | — | — | — |
| Median | — | 42.2 | 2.9 | +101.6% |